A5032970786- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Intraperitoneal and Appendiceal Malignancies
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- HER2/EGFR in Cancer Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Ovarian cancer diagnosis and treatment
- Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Gallbladder and Bile Duct Disorders
- Cancer Research and Treatments
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Occupational and environmental lung diseases
- Gastrointestinal Tumor Research and Treatment
- Colorectal and Anal Carcinomas
- Monoclonal and Polyclonal Antibodies Research
- Cancer, Lipids, and Metabolism
- Health Systems, Economic Evaluations, Quality of Life
- Renal cell carcinoma treatment
The University of Texas MD Anderson Cancer Center
2016-2025
Merck & Co., Inc., Rahway, NJ, USA (United States)
2022
Exelixis (United States)
2022
Bayer (United States)
2022
Bristol-Myers Squibb (Germany)
2022
Janssen (Belgium)
2022
GlaxoSmithKline (India)
2022
Exact Sciences (United States)
2022
John Wiley & Sons (United States)
2018
The University of Texas Health Science Center at Houston
2015
Representative racial/ethnic participation in research, especially clinical trials that establish standards of care, is necessary to minimize disparities outcomes and uphold societal equity health care.To evaluate the frequency race reporting proportional representation supporting US Food Drug Administration (FDA) oncology drug approvals.Database study all reported FDA approvals granted between July 2008 June 2018. Primary reports were obtained from PubMed ClinicalTrials.gov. identified...
<h3>Importance</h3> Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and overall 8.0 11.7 months, respectively. New treatments offering improved outcomes are therefore needed. <h3>Objective</h3> To evaluate association between addition nanoparticle albumin-bound (nab)–paclitaxel to gemcitabine-cisplatin treatment patients with cancer. <h3>Design, Setting, Participants</h3> This open-label,...
mutations are rarely associated with objective responses to the BRAF inhibitor vemurafenib in patients metastatic colorectal cancer (CRC). Blockade of
Background Colorectal cancer (CRC) incidence is increasing in adults younger than 50 years. This study evaluated clinical and molecular features to identify those unique early‐onset CRC that differentiate these patients from years old or older. Methods Baseline characteristics were according the onset age with 3 independent cohorts. A fourth cohort was used describe impact of on consensus subtype (CMS) prevalence. Results retrospective review more 36,000 showed likely have microsatellite...
Abstract Purpose: Colorectal cancers are classified as right/left-sided based on whether they occur before/after the splenic flexure, with established differences in molecular subtypes and outcomes. However, it is unclear if this division optimal precise tumor location provides further information. Experimental Design: In 1,876 patients colorectal cancer, we compared mutation prevalence overall survival (OS) according to side location. Consensus subtype (CMS) was a separate cohort of 608...
BackgroundColorectal cancer (CRC) has been shown to acquire RAS and EGFR ectodomain mutations as mechanisms of resistance epidermal growth factor receptor (EGFR) inhibition (anti-EGFR). After anti-EGFR withdrawal, mutant clones lack a advantage relative other decay; however, the kinetics decay remain unclear. We sought determine acquired RAS/EGFR after discontinuation therapy.Patients methodsWe present post-progression circulating tumor DNA (ctDNA) profiles 135 patients with RAS/BRAF...
Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy been shown to improve survival in advanced hepatocellular carcinoma; we therefore aimed evaluate the safety and tolerability of perioperative immunotherapy resectable carcinoma.
Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is not well studied the neoadjuvant space.
DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prior regimens; results primary analysis are published. Patients received T-DXd 6.4 mg/kg every 3 weeks were assigned to either: cohort A (HER2-positive, immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+), B (IHC 2+/ISH-), C 1+). Primary...
Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), median overall survival both control and experimental arms has steadily improved. However, incremental change for CRC patients not treated on trial yet been quantified. We performed a retrospective review 1420 with de novo who received their primary treatment at University Texas M.D. Anderson Cancer Center (UTMDACC) from 2004 through 2019. Median OS was roughly stable diagnosed between 2012 (22.6...
3501 Background: T-DXd (6.4 mg/kg, every 3 weeks [Q3W]) demonstrated antitumor activity in pts with HER2+ mCRC DESTINY-CRC01 (Siena et al. Lancet Oncol. 2021). We present primary results of DESTINY-CRC02 (NCT04744831), which assessed the efficacy and safety (5.4 6.4 mg/kg) mCRC. Methods: This was a multicenter phase 2 study. Eligible had centrally confirmed (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+) Pts RAS wild-type (wt) mutant (m) were eligible. received prior...
High circulating neutrophil-lymphocyte ratio (NLR) appears to be prognostic in metastatic colorectal cancer (mCRC). We investigated the relationship of NLR with cytokines and molecular alterations. performed retrospective analyses on multiple cohorts CRC patients (metastatic untreated (n=166), refractory (n=161), hepatectomy (n=198), stage 2/3 (n=274), molecularly screened (n=342)). (ratio absolute neutrophil-to-lymphocyte counts peripheral blood) was defined as NLR>5. Plasma were evaluated...
ERBB2 (HER2) amplification is an emerging biomarker in colon cancer, conferring sensitivity to combination anti-HER2 therapy. Measurement of HER2 copy number typically performed using surgical specimens, but cell-free circulating tumor DNA (ctDNA) analysis may be a noninvasive alternative. We determined the plasma (pCN) for detecting amplifications and whether pCN correlated with tissue-detected number. also assessed response HER2-targeted therapy based on suggest threshold predictive...
Background Patients with advanced rare cancers have poor prognosis and few treatment options. As immunotherapy is effective across multiple cancer types, we aimed to assess pembrolizumab (programmed cell death 1 (PD-1) inhibitor) in patients cancers. Methods In this open-label, phase 2 trial, whose tumors had progressed on standard therapies, if available, within the previous 6 months were enrolled nine tumor-specific cohorts a 10th cohort for other histologies. Pembrolizumab 200 mg was...
BackgroundCancer of unknown primary (CUP), representing approximately 3-5% all malignancies, is defined as metastatic cancer where a site origin cannot be found despite standard diagnostic workup. Because knowledge patient's remains fundamental to their treatment, CUP patients are significantly disadvantaged and most have poor survival outcome. Developing robust accessible methods for resolving tissue origin, therefore, has significant value patients.MethodsWe developed an RNA-based...
Many clinical trials supporting new drug applications underrepresent minority patients. Trials conducted by the National Cancer Institute's Clinical Trial's Network (NCTN) have greater outreach to community sites, potentially allowing better representation. We compared representation of Black patients in pharmaceutical company-sponsored cancer with NCTN and US population.
12 Background: Encorafenib (E) and cetuximab (C) offers short-lived response survival benefit for patients (pts) with MSS, BRAF V600E metastatic colorectal cancer (CRC). + EGFR inhibition induced a transient MSI-H phenotype in preclinical models of CRC may prime these tumors to immunotherapy anti-PD-1 antibodies like nivolumab (N). Methods: In this single-arm, single-institution, phase I/II clinical trial, pts treatment-refractory were eligible. No prior inhibitors, anti-EGFR antibody, or...
3560 Background: The role of immunotherapy in the treatment pMMR/MSS metastatic CRC is not established. A Japanese phase 1b trial this setting showed combination regorafenib (multikinase inhibitor with immunomodulatory activity) plus nivolumab (anti PD-1) had encouraging activity and manageable safety (Fukuoka, 2020). This study further assessed efficacy combination. Methods: Patients (pts) from US aged ≥18 years who progressed on/were intolerant to standard chemotherapy were enrolled....
299 Background: Treatment options are limited for patients with unresectable, locally advanced or metastatic BTCs progressing after first line treatment. Standard second chemotherapy yields objective response rates (ORR) of < 10% and median overall survival these is 6 months. Human epidermal growth factor receptor 2 (HER2) overexpression/ amplification observed in 5–19% BTCs. Zanidatamab a bispecific HER2-targeted antibody that has demonstrated durable single agent activity good...
Malignant peritoneal mesothelioma (MPeM) is a rare but aggressive malignancy with limited treatment options. VEGF inhibition enhances efficacy of immune-checkpoint inhibitors by reworking the immunosuppressive tumor milieu. Efficacy and safety combined PD-L1 (atezolizumab) (bevacizumab) blockade (AtezoBev) was assessed in 20 patients advanced unresectable MPeM progression or intolerance to prior platinum-pemetrexed chemotherapy. The primary endpoint confirmed objective response rate per...